ArriVent's oral lung cancer therapy fails late-stage trial, shares plunge

ArriVent BioPharma said on Tuesday its oral therapy to treat ‌patients with a rare type of lung cancer did not meet the main goal of delaying disease progression in a late-stage trial, sending ​shares...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。